Lexology January 24, 2025
BRG

How payers, providers, and life sciences companies can navigate negotiations as the fates of the Inflation Reduction Act’s (IRA) drug pricing rules, the 340B program, and Medicare Advantage hang in the balance

On October 1, 2013, Healthcare.gov officially came online as part of the Affordable Care Act’s long-awaited rollout… and went down within two hours of launch. That first day, six total users signed up for health insurance on the new site.

This initial failure—not to mention the time it took for payers to effectively price insurance in the new market—exemplifies the implementation challenges policymakers and industry can face when a healthcare law transitions from words on a page to a complex reality.

In 2025, new regulations will be put...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Payer, Pharma, Pharma / Biotech, Provider
Related Articles:
People on Ozempic may have fewer heart attacks, strokes, addictions—but more nausea, vomiting, stomach pain
Exploring the Future of Genomics and Life Sciences
How a Duty To Spend Wisely on Worker Benefits Could Loosen PBMs’ Grip on Drug Prices
Pharma is hopeful about Trump's second term — here's what to expect for drugmakers
Novo Nordisk Obesity Drug Shows 22% Weight Loss, But Lack of Safety Detail Is a Sticking Point

Share This Article